Education
About Us
Working with TipRanks
Follow Us
Bionano Genomics (BNGO)
NASDAQ:BNGO
BNGO Stock Chart & Stats
$1.62
-$0.04(-14.25%)
At close: 4:00 PM EST
$1.62
-$0.04(-14.25%)
Day’s Range― - ―
52-Week Range$1.45 - $12.57
Previous CloseN/A
Volume11.48M
Average Volume (3M)162.01K
Market Cap
$15.26M
Enterprise Value-$5.52M
Total Cash (Recent Filing)$3.06M
Total Debt (Recent Filing)$7.37M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Mar 05, 2026EPS Estimate
-1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding10,176,000
10 Day Avg. Volume126,678
30 Day Avg. Volume162,008
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.93
Price to Sales (P/S)1.07
P/FCF Ratio-0.48
Enterprise Value/Market Cap-0.36
Enterprise Value/Revenue-0.19
Enterprise Value/Gross Profit-0.41
Enterprise Value/Ebitda0.19
Forecast
1Y Price Target
$7.50Price Target Upside362.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Validation And PublicationsMultiple peer-reviewed studies demonstrating optical genome mapping utility for cancer biomarker analysis should broaden clinical acceptance and drive market adoption.
Consumables And Software GrowthShift in revenue mix toward consumables and software supports higher gross margins and creates a recurring-revenue profile as installed-system utilization rises.
ReimbursementAmerican Medical Association establishment of a second Category I CPT code for optical genome mapping increases prospects for third-party reimbursement and encourages diagnostic provider adoption.
Bears Say
ProfitabilityNet losses exceeding analyst estimates highlight ongoing operating losses that may weigh on valuation and financing flexibility.
Revenue TrendFull-year revenue decline versus the prior year indicates demand recovery may be incomplete and could pressure investor confidence in growth prospects.
Share Dilution And Valuation PressureIncrease in shares outstanding leading to a lower price objective reflects dilution risk and potential downward pressure on per-share value.
BioNano Genomics News
BNGO FAQ
What was Bionano Genomics’s price range in the past 12 months?
Bionano Genomics lowest stock price was $1.45 and its highest was $12.57 in the past 12 months.
What is Bionano Genomics’s market cap?
Bionano Genomics’s market cap is $15.26M.
When is Bionano Genomics’s upcoming earnings report date?
Bionano Genomics’s upcoming earnings report date is Mar 05, 2026 which is in 45 days.
How were Bionano Genomics’s earnings last quarter?
Bionano Genomics released its earnings results on Nov 13, 2025. The company reported -$2.04 earnings per share for the quarter, beating the consensus estimate of -$2.075 by $0.035.
Is Bionano Genomics overvalued?
According to Wall Street analysts Bionano Genomics’s price is currently Undervalued.
Does Bionano Genomics pay dividends?
Bionano Genomics does not currently pay dividends.
What is Bionano Genomics’s EPS estimate?
Bionano Genomics’s EPS estimate is -1.36.
How many shares outstanding does Bionano Genomics have?
Bionano Genomics has 10,176,000 shares outstanding.
What happened to Bionano Genomics’s price movement after its last earnings report?
Bionano Genomics reported an EPS of -$2.04 in its last earnings report, beating expectations of -$2.075. Following the earnings report the stock price went up 3.401%.
Which hedge fund is a major shareholder of Bionano Genomics?
Currently, no hedge funds are holding shares in BNGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bionano Genomics
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
BNGO Company Deck
BNGO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, record flow cell sales, and improved gross margins, with significant reductions in operating expenses. However, challenges include limited new system installations and slow market evolution in Japan. Cash reserves are solid, but a portion is restricted.View all BNGO earnings summariesBNGO Stock 12 Month Forecast
Average Price Target
$7.50
▲(362.96% Upside)
Technical Analysis
Ownership Overview
1.89% Insiders
0.51% Mutual Funds
0.41% Other Institutional Investors
96.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---